LONDON, February 20, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge has initiated coverage on the following equities: OPKO Health Inc. (NYSE: OPK), Organovo Holdings Inc. (NYSE MKT: ONVO), Neuralstem Inc. (NYSE MKT: CUR), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), and Raptor Pharmaceutical Corporation (NASDAQ: RPTP). Free research report on OPKO Health can be accessed at http://get.Investor-Edge.com/pdf/?c=OPKO%20Health&d=20-Feb-2015&s=OPK. On Thursday, February 19, 2015, the NASDAQ Composite ended at 4,924.70, up 0.37%, the Dow Jones Industrial Average declined 0.24%, to finish the day at 17,985.77, and the S&P 500 closed at 2,097.45, down 0.11%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 825.10, up 0.09%, with the index also advancing 4.55% in the previous three months. Register for your complimentary reports at the links given below.

OPKO Health Inc.'s stock advanced 2.21%, to close the day at $14.36. The stock recorded a trading volume of 2.93 million shares, below its three months average volume of 3.50 million shares. The stock oscillated between $14.01 and $14.40 during the session. Over the last one month and over the past three months, OPKO Health Inc.'s shares have surged 43.31% and 75.98%, respectively. Further, the stock has rallied 69.34% in the previous year. The company is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $10.77 is above its 200-day moving average of $9.17. Additionally, OPKO Health Inc.'s stock has a Relative Strength Index (RSI) of 77.08. Sign up and read the free notes on OPK at:

http://get.Investor-Edge.com/pdf/?c=OPKO%20Health&d=20-Feb-2015&s=OPK

On Thursday, shares in Organovo Holdings Inc. recorded a trading volume of 0.71 million shares, lower than its three months average volume of 1.08 million shares. The stock ended the day at $6.33, which was 2.76% below its previous day's closing of $6.51, and registered an intraday range of $6.30 and $6.50. Although Organovo Holdings Inc.'s shares have advanced 2.76% in the last one month, it has lost 0.16% in the previous three trading sessions and 35.80% in the past one year. The company is trading below its 50-day and 200-day moving averages of $6.51 and $6.91, respectively. Furthermore, shares of Organovo Holdings Inc. have an RSI of 53.79. The complimentary notes on ONVO can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Organovo%20Holdings&d=20-Feb-2015&s=ONVO

Neuralstem Inc.'s stock closed Thursday's session flat at $3.83, after oscillating between $3.67 and $3.92. The stock recorded a trading volume of 1.28 million shares, above its three months average volume of 0.85 million shares. Over the last one month and the previous three months, Neuralstem Inc.'s shares have surged 27.24% and 38.27%, respectively. Additionally, the stock has gained 15.02% in the last one year. The company is trading above its 50-day and 200-day moving averages. The stock's 200-day moving average of $3.32 is above its 50-day moving average of $3.02. Further, Neuralstem Inc.'s stock has an RSI of 69.81. Register for free on Investor-Edge and access the latest research on CUR at:

http://get.Investor-Edge.com/pdf/?c=Neuralstem&d=20-Feb-2015&s=CUR

Regeneron Pharmaceuticals Inc.'s stock finished Thursday's session 5.13% higher at $426.60. A total of 1.45 million shares were traded, which was above its three months average volume of 0.80 million shares. The stock moved between $407.49 and $428.47 during the session. Regeneron Pharmaceuticals Inc.'s shares have gained 6.01% in the previous three trading sessions and 4.38% in the last one month. Additionally, the stock has gained 31.52% in the past one year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $411.11 is greater than its 200-day moving average of $357.90. Regeneron Pharmaceuticals Inc.'s stock traded at a PE ratio of 131.22 and has an RSI of 48.52. The complete research on REGN is available for free at:

http://get.Investor-Edge.com/pdf/?c=Regeneron%20Pharma&d=20-Feb-2015&s=REGN

On Thursday, shares in Raptor Pharmaceutical Corp. fluctuated between $9.41 and $9.70 before ending the session 1.80% higher at $9.64. The stock reported a trading volume of 0.94 million shares, above its three months average volume of 0.76 million shares. Although, Raptor Pharmaceutical Corp.'s shares have advanced 6.52% in the previous three trading sessions, it has lost 2.92% in the last three months and 35.39% in the past one year. The company is trading above its 50-day moving average of $9.39. Moreover, shares of Raptor Pharmaceutical Corp. have an RSI of 51.70. Free in depth research on RPTP is available at:

http://get.Investor-Edge.com/pdf/?c=Raptor%20Pharma&d=20-Feb-2015&s=RPTP

About Investor-Edge.com

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge